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INTRODUCTION: 
Benzimidazole is very useful heterocyclic 
compound/intermediate for the development of 
molecules of pharmaceutical or biological interest.1 
Derivatives of benzimidazole possess a wide range of 
pharmacological activities such as Anti-neoplastic, 
analgesic, Anthelmintics, Anti-ulcer, anti-inflammatory, 
Antifungal, Anti-histaminic, Antiviral and Anti-
diabetic.2-7 
Numerous publication have shown that benzimidazole 
derivatives also have anticonvulsant activity.8-12  
An attempt has been made in our study to synthesize 
Benzimidazole acetohydrazide derivatives to get as 
potent anticounvulsant compounds. The newly 
synthesized Benzimidazole acetohydrazide derivatives 
were evaluated for anticonvulsant activity by the MES 
method using phenytoin as standard. 
MATERIAL AND METHODS: 
1H-benzimidazole (1a). A mixture of o-
phenylenediamine (27 g, 0.25 mol) and formic acid (16 
ml, 85 %) was refluxed on a water bath for 2 h. The 
reaction mixture was cooled and its pH was adjusted to 8 
by addition of sodium hydroxide (10 %) solution. The 
crude product so obtained was filtered, thoroughly 
washed with ice cold water and dried. The dried product 
was boiled with decolourising charcoal (2 g) in water 
(400 ml) for 15 min and filtered while hot. The solution 
thus obtained was allowed to cool at 10 °C for 30 min, 
filtered and dried. The completion of reaction was 
monitored by running TLC.  
Yield: 88 %, Rf value: 0.46, M.p. 170-172 ºC. IR (KBr in 
cm-1): 3115 (N-H), 3048 (Ar. C-H), 1362 (C=N). Anal. 
calcd. for C7H6N2 (118.14): C, 71.17; H, 5.12; N, 23.71. 
Found: C, 71.22; H, 5.16; N, 23.31 %. LCMS m/z: 118.1 
(M+).
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Scheme 1 Reaction Protocol for the synthesis of 3a-3f 
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ABSTRACT:  
A series of some novel benzimidazole acetohydrazide derivatives was synthesized and characterized by TLC, MP, elemental 
analysis, IR, Mass and 1H NMR spectroscopy. These compounds were screened for anticonvulsant activities by Maximum 
Electroshock seizure model in male wistar rats and compared with the standard drug phenytoin.  
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Similar procedure was used to prepare 1b-1f by using 
corresponding aliphatic and aromatic carboxylic acid. 
2-Methyl-1H-benzimidazole (1b): Yield: 76 %, Rf value: 
0.39, M.p. 174-176 ºC. IR (KBr in cm-1): 3194 (N-H), 
3066, 2998(Ar. C-H), 1386(C=N). Anal. calcd. for 
C8H8N2 (132.16): C, 72.70; H, 6.10; N, 21.20 %. Found: 
C, 72.57; H, 6.04; N, 21.12 %. LCMS m/z: 132.1 (M+). 
2-Benzyl-1H-benzimidazole (1c): Yield: 79 %, Rf value: 
0.67, M.p. 192-194 ºC. IR (KBr in cm-1): 3023 (N-H), 
2964(Ar. C-H), 2614(-CH2), 1418(C=N). Anal. calcd. for 
C14H12N2 (208.26: C, 80.74; H, 5.81; N, 13.45 %. Found: 
C, 80.63; H, 5.92; N, 13.61 %. LCMS m/z: 208.1 (M+). 
2- Phenyl-1H-benzimidazole (1d): Yield: 81 %, Rf value: 
0.57, M.p. 290-292 ºC. IR (KBr in cm-1): 3183 (N-H), 
2943(Ar. C-H), 1427 (C=N). Anal. calcd. for C13H10N2 
(194.23): C, 80.39; H, 5.19; N, 14.42 %. Found: C, 
80.51; H, 5.26; N, 14.23 %. LCMS m/z: 195.1 (M+). 
2-(4-Chlorophenyl)-1H-benzimidazole (1e): Yield: 87 %, 
Rf value: 0.77, M.p. 234-236 ºC. IR (KBr in cm
-1): 3188 
(N-H), 2971(Ar. C-H), 1412 (C=N), 816 (C-Cl). Anal. 
calcd. for C13H9ClN2 (228.68): C, 68.28; H, 3.97; N, 
12.25 %. Found: C, 68.39; H, 4.03; N, 12.36 %. LCMS 
m/z: 228.3. 
4-Dimethyl aminophenyl-1H-benzimidazole (1f): Yield: 
83 %, Rf value: 0.66, M.p. 176-178 ºC. IR (KBr in cm
-1): 
3192 (N-H), 2987 (Ar. C-H), 1428 (C=N), 1293 (C-N). 
Anal. calcd. for C15H17N3 (239.32): C, 75.28; H, 7.16; N, 
17.56 %. Found: C, 75.34; H, 7.23; N, 17.62 %. LCMS 
m/z: 239.6 (M+). 
Ethyl-2-(1H-benzimidazol-1-yl)ethanoate (2a): A 
solution of Benzimidazole 1a (3.54 g, 0.03 mol) in 
acetone was refluxed with chloroethylacetate (3.69 g, 
3.20 ml, 0.03 mol) and potassium carbonate (8.28 g, 0.06 
mol) for 4 h. The reaction mixture was filtered while hot 
and evaporated to dryness. The completion of reaction 
was monitored by running TLC. 
Yield: 74 %, Rf value: 0.49, M.p.160-164 ºC. IR (KBr in 
cm-1): 2978 (Ar H str), 1689 (C=O),1396 (tert. N), 1226 
(C-O). Anal. calcd. for C11H12N2O2 (204.23): CC, 64.69; 
H, 5.92; N, 13.72 %. Found: C, 64.82; H, 5.76; N, 13.63 
%. LCMS m/z: 205.1 (M+). 
Similar procedure was used to prepare 2b-2f by using 
corresponding 2-subtituted benzimidazoles (1b-1f). 
Ethyl-2-(2-methyl-1H-benzimidazol-1-yl)ethanoate (2b): 
Yield: 79 %, Rf value: 0.68, M.p. 80-82 ºC. IR (KBr in 
cm-1): 2998 (Ar H str), 1692 (C=O),1387 (tert. N), 1248 
(C-O). Anal. calcd. for C17H19N5O (309.37): C, 66.00; H, 
6.19; N, 22.64 %. Found: C, 65.91; H, 6.24; N, 22.55 %. 
LCMS m/z: 309.2 (M+). 
Ethyl-2-(2-benzyl-1H-benzimidazol-1-yl)ethanoate (2c): 
Yield: 83 %, Rf value: 0.49, M.p. 92-96 ºC. IR (KBr in 
cm-1): 2974 (Ar H str), 1678 (C=O), 1392 (tert. N), 1253 
(C-O). Anal. calcd. for C18H18N2O2 (294.35): C, 73.45; 
H, 6.16; N, 9.52 %. Found: C, 73.61; H, 6.19; N, 9.67 %. 
LCMS m/z: 294.14 (M+). 
Ethyl-2-(2-phenyl-1H-benzimidazol-1-yl)ethanoate (2d): 
Yield: 81 %, Rf value: 0.69, M.p. 74-78 ºC. IR (KBr in 
cm-1): 2963 (Ar H str), 1689 (C=O), 1374 (tert. N), 1265 
(C-O). Anal. calcd. for C17H16N2O2 (280.32): C, 72.84; 
H, 5.75; N, 9.99 %. Found: C, 72.79; H, 5.81; N, 9.79 %. 
LCMS m/z: 280.1 (M+). 
Ethyl-2-(2-(4-chloro)phenyl-1H-benzimidazol-1-
yl)ethanoate (2e): Yield: 67 %, Rf value: 0.53, M.p. 88-
90 ºC. IR (KBr in cm-1): 2943 (Ar H str), 1678 (C=O), 
1381 (tert. N), 1272 (C-O), 8-24 (C-Cl). Anal. calcd. for 
C17H15ClN2O2 (314.77) C, 64.87; H, 4.80; N, 8.90 %. 
Found: C, 64.92; H, 4.89; N, 8.78 %. LCMS m/z: 314.1 
(M+). 
Ethyl 2-(2-(4-dimethyl amino)phenyl-1H-benzimidazol-
1-yl)ethanoate (2f): Yield: 88 %, Rf value: 0.76, M.p. 
102-106 ºC. IR (KBr in cm-1): 1H-NMR (DMSO δ ppm): 
. Anal. calcd. for C19H21N3O2 (323.39): C, 70.57; H, 
6.55; N, 12.99 %. Found: C, 70.72; H, 6.61; N, 12.93 %. 
LCMS m/z: 323.2 (M+). 
2-(1H-Benzimidazol-1-yl) acetohydrazide (3a): A 
mixture of Ethyl-2-(1H-benzimidazol-1-yl) ethanoate 2a 
(2.04 g, 0.01 mol) and hydrazine hydrate (0.75 g, 0.73 
ml, 0.015 mol) in ethanol (25 ml) was refluxed on a 
water bath for 3 h. The reaction mixture was cooled, 
made acidic to get precipitate. The separated solid was 
filtered and purified by recrystallisation from ethanol. 
The completion of reaction was monitored by running 
TLC. Yield: 73 %, Rf value: 0.65, M.p. 180-182 ºC. IR 
(KBr in cm-1): 3362 (NH), 2972 (Ar C-H str), 1689 
(C=O), 1391 (tert. N). 1H-NMR (DMSO δ ppm): 7.92 (s, 
1H, Ar-CH), 7.23-7.73 (m, 4H, Ar-CH), 6.34 (s, 1H, 
NH), 5.29 (s, 2H, CH2), 3.39-3.44 (s, 2H, NH2). Anal. 
calcd. for C9H10N4O (190.2): C, 56.83; H, 5.30; N, 29.46 
%. Found: C, 56.63; H, 5.23; N, 29.29 %. LCMS m/z: 
190.1 (M+). 
Compounds (2b-2f) were used to prepare 3b-3f by using 
similar procedure. 
2-(2-Methyl-1H-benzimidazol-1-yl)acetohydrazide (3b): 
Yield: 79 %, Rf value: 0.29, M.p. 240-242 ºC. IR (KBr in 
cm-1): 3455(NH), 3138(NH), 3051, 2905(Ar CH str), 
1635(C=O), 1510(C=N), 1323(tert. N), 1290(C-N). 1H-
NMR (DMSO δ ppm): 7.14-7.59 (m, 4H, Ar-CH), 6.28 
(s, 1H, NH), 5.23 (s, 2H, CH2), 3.29-3.31 (s, 2H, NH2), 
2.58 (s, 3H, CH3). Anal. calcd. For C10H12N4O (204.23): 
C, 58.81; H, 5.92; N, 27.43; O, 7.83 %. Found: C, 58.81; 
H, 5.87; N, 27.53; O, 7.69 %. LCMS m/z: 204.6 (M+). 
2-(2-Benzyl-1H-benzimidazol-1-yl)acetohydrazide (3c): 
Yield: 82 %, Rf value: 0.36, M.p. 184-186 ºC. IR (KBr in 
cm-1): 3342 (-NH), 2894 (Ar CH str), 1652 (C=O), 1509 
(C=N), 1328 (tert. N), 1310 (C-N). 1H-NMR (DMSO δ 
ppm): 7.09-7.64 (m, 9H, Ar-CH), 6.47 (s, 1H, NH), 5.16 
(s, 2H, CH2), 3.94 (s, 2H, CH2), 3.29-3.31 (s, 2H, NH2). 
Anal. calcd. for C16H16N4O (280.32): C, 68.55; H, 5.75; 
N, 19.99 %. Found: C, 68.73; H, 5.82; N, 19.86 %. 
LCMS m/z: 280.1 (M+). 
2-(2-Phenyl-1H-benzimidazol-1-yl)acetohydrazide (3d): 
Yield: 79 %, Rf value: 0.36, M.p. 294-298 ºC. IR (KBr in 
cm-1): 3358 (NH), 3051, 2961 (Ar H str), 1696 (C=O), 
1380 (tert. N). 1H-NMR (DMSO δ ppm): 7.11-7.86 (m, 
9H, Ar-CH), 6.29 (s, 1H, NH), 5.27 (s, 2H, CH2), 3.08 (s, 
2H, NH2). Anal. calcd. for C15H14N4O (266.3): C, 67.65; 
H, 5.30; N, 21.04 %. Found: C, 67.75; H, 5.49; N, 21.14 
%. LCMS m/z: 266.1 (M+). 
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2-(2-(4-Chloro) phenyl-1H-benzimidazol-1-
yl)acetohydrazide (3e): Yield: 74 %, Rf value: 0.29, M.p. 
252-256 ºC. IR (KBr in cm-1): 3369 (NH), 2914 (Ar H 
str), 1699 (C=O), 1375 (tert. N), 733 (C-Cl). 1H-NMR 
(DMSO δ ppm): 7.03-7.68 (m, 8H, Ar-CH), 6.34 (s, 1H, 
NH), 5.19 (s, 2H, CH2), 3.13 (s, 2H, NH2). Anal. calcd. 
for C15H13ClN4O (300.74): C, 59.91; H, 4.36; Cl, 11.79; 
N, 18.63 %. Found: C, 59.82; H, 4.24; N, 18.48 %. 
LCMS m/z: 300.1(M+). 
2-(2-(4-Dimethyl amino) phenyl-1H-benzimidazol-1-
yl)acetohydrazide (3f): Yield: 85 %, Rf value: 0.73, M.p. 
204-206 ºC. IR (KBr in cm-1): 3380 (NH), 2924 (Ar H 
str), 1681 (C=O), 1384 (tert. N). 1H-NMR (DMSO δ 
ppm): 7.01-7.61 (m, 8H, Ar-CH), 6.42 (s, 1H, NH), 5.28 
(s, 2H, CH2), 3.18 (s, 2H, NH2), 2.89 (s, 6H, N(CH3)2). 
Anal. calcd. for C17H19N5O (309.37): C, 66.00; H, 6.19; 
N, 22.64 %. Found: C, 66.11; H, 6.12; N, 22.52 %. 
LCMS m/z: 309.2 (M+). 
Pharmacology 
Animals: Male wistar rats procured from BN College of 
Pharmacy, Udaipur (150-200 g) were used in the present 
study. The animals were housed in colony cages, 
conditions of constant temperature (22±2 °C), a 12 h 
light/dark schedule, and allowed free access to standard 
diet and tap water except during the experiment. The 
animals were allowed to habituate to the laboratory 
environment for 24 h before the experiments were 
initiated.  
All the experimental procedures were carried out in 
accordance with Committee for the Purpose of Control 
and Supervision of Experiments on Animals (CPCSEA) 
guidelines. The protocol of the study was approved by 
Institutional Animal Ethical Committee. 
Anticonvulsant activity  
Maximal Electroshock Seizure Model (MES): Maximal 
electroshock seizure model was used in the present study 
to evaluate the anticonvulsant activity of the compounds 
on male wistar rats. Seizures were induced in rats by 
delivering electroshock of 150 mA for 0.2 sec by means 
of an electro-convulsiometer through a pair of ear clip 
electrodes. The test compounds (100 mg/kg) were 
administered by oral route in the form of solution (The 
compounds were dissolved in 1% sodium carboxymethyl 
cellulose), 30 min before the maximal electroshock 
seizure (MES) test.13 Phenytoin (100 mg/kg) was used as 
a standard drug. The reduction in time or abolition of 
tonic extensor phase of MES- convulsions was noted.14 
The data are calculated & expressed as mean extensor 
phase duration in sec. followed by % protection and % 
potency in comparison with the standard as shown in 
Table 1 using the following formula:  
% Protection = (MEPDnc - MEPDsample/ MEPD) X100 
Where MEPDnc is the mean extensor phase duration of 
normal control in sec. and MEPD is the mean extensor 
phase duration of sample or standard in sec. 
% Potency = (MEPDnc - MEPD/ MEPDnc -MEPDstd) X 100 
Where MEPDstd is the mean extensor phase duration of 
standard control in sec. 
Statistical analysis 
The results are expressed as the mean±SEM per group 
and the data were analyzed by one-way analysis of 
Variance (ANOVA) followed by Dunnett’s test as post 
hoc test.  p value <0.05 was considered statistically 
significant.
 
Table 1 Anticonvulsant activity of title compounds 
Compound 
Nos. 
Dose 
(mg/kg) 
Extensor phase  
duration(Sec.) 
Protection 
(%) 
Potency 
(%) 
Control  - 18.4±0.927 - - 
Phenytoin 100 7.6±0.509** 58.69 100 
3a 100 14.8±0.860
** 19.56 33.33 
3b 100 13.0±0.447
** 29.35 50.00 
3c 100 12.6±0.678
** 31.52 53.70 
3d 100 17.6±0.812
ns 4.35 7.41 
3e 100 15.6±1.116
ns 15.22 25.92 
3f 100 15.2±0.374
* 17.39 29.63 
 
Data analyzed by one way ANOVA followed by 
Dunnett’s test, (n = 6), *P < 0.05, **P < 0.01 significant 
from control; ns, not significant. 
RESULTS & DISCUSSION: 
All title compounds were synthesized as per Scheme 1 
and their structure was confirmed by IR, 1H NMR, 
LCMS, and elemental analysis. The anticonvulsant 
activity was determined by MES method on wistar rats 
using phenytoin as standard drug (Table 1). Compounds 
3a, 3b, 3c and 3f showed significant protection against 
maximum electroshock seizures. Compounds 3b and 3c 
exhibited more potent activity than that of other 
compounds. Compound 3c was found to be most potent 
among all the compounds.   
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